Imaging features based on CT and MRI for predicting prognosis of patients with intrahepatic cholangiocarcinoma: a single-center study and meta-analysis

Table 5 Predictor studies eligible for net Meta-analysis about adjusted HRs

Study ID	Country	Imaging examination method	Definition of disease	NO.of Hypoenhancement at arterial phase	NO.of Peripheral enhancement	NO.of Hyperenhancement at arterial phase	Form of comparison	Follow-up years	Primary endpoints	HR estimate	HR	95%CI	P value	NOS score	K value
Min 2019 [22]	Korea	MRI	IMCC	33	81	20	Hypo:Hyper	8	OS	paper	41.00	5.00–312.00	< 0.010	8	NA
							Peri:Hyper		OS		11.00	2.00–85.00	0.020
							Hypo:Hyper		EFS		3.50	1.40–8.60	< 0.010
							Peri:Hyper		EFS		1.70	0.70–3.90	0.230
Hyeong 2022 [37]	Korea	CT	ICC	60	56	23	Hypo:Hyper	15	EFS	paper	3.89	1.70–8.91	0.001	8	NA
Hyeong 2022 [37]	Korea	CT	ICC	60	56	23	Peri:Hyper	15	EFS	paper	6.24	2.67–14.59	< 0.001	8	NA
Panettieri 2021 [23]	USA	CT	ICC	10	29	17	Hypo:Hyper	5	OS	paper	5.33	1.52–19.90	0.009	7	NA
							Peri:Hyper		OS		1.65	0.67–4.09	0.280
							Hypo:Hyper		EFS		3.22	1.08–9.56	0.036
							Peri:Hyper		EFS		1.75	0.75–4.08	0.192
This study	China	CT	ICC	68	60	33	Hypo:Hyper	15	OS	paper	5.32	2.56–11.03	< 0.001	8	NA
							Peri:Hyper		OS		2.93	1.46–5.87	0.002
							Hypo:Hyper		EFS		4.27	2.21–8.25	< 0.001
							Peri:Hyper		EFS		3.52	1.85–6.71	< 0.001
		MRI		12	15	16	Hypo:Hyper		OS		5.14	1.32–19.97	0.018
							Peri:Hyper		OS		3.08	0.80–11.84	0.101
							Hypo:Hyper		EFS		3.94	1.12–13.89	0.033
							Peri:Hyper		EFS		2.63	0.75–9.18	0.129
Jin 2022 [40]	China	MRI	IMCC	56	142	33	Hypo:Hyper	8	OS	paper	NA	NA	NA	8	NA
							Peri:Hyper		OS		NA	NA
							Hypo:Hyper		EFS		NA	NA
							Peri:Hyper		EFS		NA	NA
Park 2021 [30]	Korea	CT	IMCC	100	111	22	Hypo:Hyper	10	EFS	paper	NA	NA	NA	7	0.99
Park 2021 [30]	Korea	CT	IMCC	100	111	22	Peri:Hyper	10	EFS	paper	NA	NA	NA	7	0.99

ISSN: 1470-7330